Journal Article

Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin

Wang, Runming, Yan, Aixin, Zhang, Qi, Ho, Pak-Leung, Wang, Minji, Li, Hongyan, Wang, Haibo, Hao, Quan, Sun, Hongzhe, Kao, Richard Yi-Tsun, Wong, Yuen-Ting

2020

Overview

Global emergence of Gram-negative bacteria carrying the plasmid-borne resistance genes, bla MBL and mcr , raises a significant challenge to the treatment of life-threatening infections by the antibiotics, carbapenem and colistin (COL). Here, we identify an antirheumatic drug, auranofin (AUR) as a dual inhibitor of metallo-β-lactamases (MBLs) and mobilized colistin resistance (MCRs), two resistance enzymes that have distinct structures and substrates. We demonstrate that AUR irreversibly abrogates both enzyme activity via the displacement of Zn(II) cofactors from their active sites. We further show that AUR synergizes with antibiotics on killing a broad spectrum of carbapenem and/or COL resistant bacterial strains, and slows down the development of β-lactam and COL resistance. Combination of AUR and COL rescues all mice infected by Escherichia coli co-expressing MCR-1 and New Delhi metallo-β-lactamase 5 (NDM-5). Our findings provide potential therapeutic strategy to combine AUR with antibiotics for combating superbugs co-producing MBLs and MCRs. Multi-drug resistant pathogens remain a serious public health threat. Here, Sun and colleagues identify a role for auranofin, which is normally used as a drug for rheumatoid arthritis, for reversing antibiotic resistance to carbapenem and colistin.

• Publisher: Nature Publishing Group UK,Nature Portfolio
• Subject: 45/77 / 631/326/22 / 631/45/321 / 639/638/309/152 / 64/60 / 692/699/255/1318 / 82/83 / 96/1 / Humanities and Social Sciences / multidisciplinary / Science / Science (multidisciplinary)